Physeon GmbH to Present at MedTech Strategist Innovation Summit - Dublin, Ireland April 17-19, 2018
Physeon GmbH / Physeon GmbH to Present at MedTech Strategist Innovation Summit - Dublin, Ireland April 17-19, 2018 . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Company's New CEO Patrick Kullmann to Present on Opportunity for Novel and Disruptive Veinplicity Device
SCHAFFHAUSEN, Switzerland, March 26, 2018 (GLOBE NEWSWIRE) -- Physeon® GmbH, ("Physeon" or the "Company"), a leading developer of medical technology products for venous access, today announced that the Company will be a guest presenter at the "MedTech Strategist Innovation Summit" meeting to be held in Dublin, Ireland April 17-19, 2018.
This meeting is one of the largest of its kind outside of the US for MedTech companies and investors alike. The three-day meeting will match companies with potential investors, CEOs and scientist-entrepreneurs in the highly respected venue of Dublin, Ireland, a country rich in Medtech industry.
The conference includes more than 400 top medical device venture capitalists and senior business development executives from Ireland, many other European countries, the US, Asia, and beyond, along with management teams from many of the most promising start-ups in the device space. Additionally, the conference is an excellent venue for early stage life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually secure funding.
Patrick Kullmann, Physeon's Chief Executive Officer and event presenter commented on the market opportunity for Physeon and the Veinplicity® product, "Veinplicity is designed to aid peripheral IV cannulation, the single most common medical intervention performed each day in hospitals. Although up to 80% of patients need a peripheral IV cannula, a significant proportion of the population have veins that are difficult to access. Successful venous cannulation is challenged by a patient's anatomy and disease state amongst other factors and failure leads to delayed treatment, increased costs and patient discomfort."
Kullmann added, "Veinplicity addresses these challenges by significantly increasing the size, rigidity and stability of forearm veins, making them easier to find and easier to cannulate the first time. Consisting of a portable electronic stimulation device which passes a gentle current between electrodes placed on the palm and the bicep, Veinplicity is the only technology available which has a physiological effect on veins. The system perfectly fits the 'razor-razor blade' medical model for success."
Veinplicity is CE Marked and is available outside the US, it is not FDA approved and not for sale in the US.
Established in 2015 and located in Schaffhausen, Switzerland, Physeon is a boutique medical device company created to guide the development and commercialization of new innovations in healthcare. We embrace research and science to bring about innovative ideas and medical products that can advance the health and well-being of patients and simplify processes for healthcare professionals. Veinplicity is CE marked and is available on a limited basis in the EU. It is not yet FDA approved and is not yet commercially available in the US. For more information, visit www.physeon.com.
+41 78 683 2452
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Physeon GmbH via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
SpeeDx and Serosep sign UK and Ireland distribution agreement23.4.2018 07:00 | Pressemelding
SpeeDx has announced a distribution agreement with Serosep Ltd, a leading manufacturer and distributor of laboratory diagnostic solutions. This will strengthen sales channels in the UK and Ireland, ensuring greater access to SpeeDx's multiplexed Plex PCR ® and Resistance Plus ® molecular diagnostic tests across the region. The agreement provides Serosep customers with access to SpeeDx's proprietary technology for infectious disease diagnostics, in line with Serosep's goal of improving lives while supporting the everyday struggles faced by laboratories. The SpeeDx portfolio includes the market-leading Resistance Plus MG assay - for simultaneous detection of Mycoplasma genitalium and genetic markers for azithromycin resistance - as well as a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis). Further Resistance Plus assays will be released later this year - including a test for gonorrhoea - along with a comprehensive Plex PCR multiplex p
Winners in 2018 Asia-Pacific Stevie® Awards Announced23.4.2018 04:00 | Pressemelding
Honorees for Innovation in Business to Be Recognized in Hong Kong on 1 June FAIRFAX, Va., April 22, 2018 (GLOBE NEWSWIRE) -- Winners in the fifth annual Asia-Pacific Stevie® Awards, the only awards program to recognize innovation in business throughout the entire Asia-Pacific region, were announced today. The list of Gold, Silver and Bronze Stevie Award winners is available at http://Asia.StevieAwards.com. The Stevie Awards are considered to be the world's premier business awards, conferring recognition for achievement in the workplace over the past 16 years in programs such as The International Business Awards® and The American Business Awards®. The 2018 Asia-Pacific Stevie Awards have recognized organizations in 14 nations including Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, Philippines, Singapore, South Korea, Taiwan, Thailand, the U.S.A. and Vietnam. More than 800 nominations about innovative achievements in the 22-nation APAC region were considered by the judges
Gratomic and Perpetuus Carbon Technologies Limited Enter Into an Agreement for the Exclusive Development and Marketing of Material Enhancing Graphenes Derived From Gratomic Aukam Graphite22.4.2018 22:00 | Pressemelding
TORONTO, April 22, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A2JAP3). Gratomic Inc., is pleased to announce that the Company has signed a letter of collaboration ("Agreement") with Perpetuus Carbon Technologies Limited ("Perpetuus") pursuant to which GRAT and Perpetuus will develop and market material enhancing graphite derived graphenes and graphene hybrids for tire elastomers, whilst also exploring options to exploit polymer composites, energy capture and storage applications markets ("Project"). The Agreement contemplates the first Phase of the Project ("Phase 1"), with the other phases to be described in a joint venture agreement to be entered into between GRAT and Perpetuus. Pursuant to the Agreement, and as part of Phase 1, GRAT will purchase, and retain ownership, of three specialised process tooling chambers at an aggregate cost of 300,000 British Pounds. These specialized tooling chambers will be housed in Perpetuus' ex
Abeona Therapeutics Receives Orphan Drug Designation in the European Union for ABO-202 Gene Therapy Program in Batten Disease20.4.2018 14:15 | Pressemelding
NEW YORK and CLEVELAND, April 20, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products has granted Orphan Drug Designation (EMA/OD/013/18) for Abeona's gene therapy program ABO-202 for the treatment of subjects with neuronal ceroid lipofuscinosis, also known as Batten Disease, a fatal lysosomal storage disease that primarily affects the nervous system in children. ABO-202 is an adeno-associated virus developed to introduce a functional copy of the CLN1 gene into cells in order to restore the enzyme activity that is needed to break down certain lipopigment proteins that are deficient in patients with CLN1 disease. "This designation is an important step in our CLN1 program as it encourages us to proceed towards clinical development," st
Taconic Biosciences Licenses Easi-CRISPR Technology from the University of Nebraska20.4.2018 14:00 | Pressemelding
RENSSELAER, N.Y., April 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered mouse model and service solutions, has been granted a license to the Easi-CRISPR technology from the University of Nebraska. Easi-CRISPR was developed in the laboratories of Drs. Masato Ohtsuka (Tokai University in Japan), and Channabasavaiah Gurumurthy (University of Nebraska). The terms of the agreement include a world-wide, non-exclusive license to the technology, allowing Taconic rights to generate and sell rodent models generated via Easi-CRISPR. When compared to traditional CRISPR, Easi-CRISPR represents a significant advantage, allowing researchers to perform whole genetic insertions versus being limited to point mutations and constitutive knockouts. "Easi-CRISPR is the next progression of the revolutionary CRISPR/Cas technology. Combining the speed of CRISPR with larger genetic insertions allows complex projects typically requiring homologous recombinati
PayByPhone appoints Andreas Gruber as new President and CEO20.4.2018 00:19 | Pressemelding
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- PayByPhone, the global leader in mobile parking payments, today announced that it will appoint Andreas Gruber as president and Chief Executive Officer effective June 1st, 2018. Francis Dupuis, the former President and CEO, will take over a position in Germany with parent company Volkswagen Financial Services AG. To provide additional impetus to the PayByPhone board, two new board positions have been created and as a result Maggie Clay (CFO) and Catherine Scott (Legal Counsel) will be appointed effective June 1st, 2018. During his time at PayByPhone, Francis led the business through significant growth and organizational change and leaves the company well positioned for continued success. "We would like to thank Francis for his strong leadership and look forward to building on his experience within Volkswagen Financial Services," Gerd Künne, Vice-President of mobility unit at Volkswagen Financial Services, said. Francis is e
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom